Meeting
2020 Gastrointestinal Cancers Symposium
Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients (pts) with malignant ascites.
Authors
Akinori Sugaya
Division of Medical Oncology, Ibaraki Prefectural Hospital, Kasama, Japan
Akinori Sugaya , Shunsuke Ueyama , Hirosumi Suzuki , Takeshi Yamada , Yoshiyuki Yamamoto , Toshikazu Moriwaki , Ichinosuke Hyodo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 392)
Abstract #
392
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
First Author: Keitaro Shimozaki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
First Author: Ilya Tsimafeyeu
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif